Search

News Proton radiotherapy in patients with nasopharyngeal carcinoma increases chances of successful treatment

Nasopharyngeal carcinoma mainly affects younger people. It tends to be aggressive but responds very well to treatment –⁠ up to 85% of patients with this diagnosis can achieve long-term tumor disappearance with proton radiotherapy, and a significant portion of patients even completely recover. The two-year treatment results for patients with very advanced nasopharyngeal tumors, which confirmed these conclusions, were published 2 years ago by a team from Prague's Proton Therapy Center (PTC).

Source: Proton Radiotherapy 20. 9. 2023

News Advances in the Treatment of Myasthenia Gravis on the Horizon

The research of new drugs for the generalized form of myasthenia gravis has made significant progress in recent years. How is the new specific therapy performing? And are we heading towards a radical change in treatment strategy?

Source: Rare Diseases in Neurology 28. 3. 2024

News Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?

Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive fibrotic phenotype" in research mean? And what would a change in classification mean for patients?

Source: Progressive Interstitial Pulmonary Processes 9. 9. 2021

News Can the Fixed Combination of Tramadol/Acetaminophen Significantly Reduce Back Pain Uncontrolled by NSAIDs?

One way to prevent drug-related complications in the treatment of lower back pain (LBP) while improving patients' functioning in daily activities is the prescription of the weak opioid agonist tramadol in combination with acetaminophen. A smaller Japanese observational study focused on the effectiveness of this treatment in reducing the disability of patients with chronic LBP, improving their daily activities, and the occurrence of adverse events.

Source: Pharmacotherapy of Pain 9. 10. 2020

News Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice –⁠ Results from the VILP Registry

At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's 15th PragueONCO, results from the Czech VILP registry were presented. This registry collected data on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with pegylated liposomal irinotecan (nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV). The efficacy and safety of nal-IRI + 5-FU/LV in patients with mPDAC after failure or intolerance to gemcitabine-based chemotherapy, as found in the randomized controlled study NAPOLI-1, are thus confirmed in real clinical practice in the Czech Republic.

Source: Treatment of Gastrointestinal Carcinomas 25. 3. 2024

News Traveling with MS –⁠ Is Vaccination a Limitation?

What about the need for vaccination when traveling abroad? Which vaccines should you be cautious about? And how to time vaccination concerning disease activity and the individual medications used in multiple sclerosis (MS) therapy?

Source: Multiple Sclerosis 5. 6. 2023

News Indication of Bilastine in Specific Patient Groups −⁠ Practical Tips for Clinical Practice

Bilastine is a non-sedating H1-antihistamine, which is very well tolerated by patients. It can be indicated in the therapy of allergic diseases in both pediatric and adult populations. What are the possibilities of its use in specific patient groups?

Source: Allergic Reactions 24. 5. 2022

Články časopisu Fatal meningococcal sepsis caused by Neisseria meningitidis serogroup W

Author of the article: L. Krbková, M. Fedora, J. Pavelka, P. Křížová, K. Labská, Z. Vacková Source: Česko-slovenská pediatrie | 5/2017 9. 10. 2017

News Inosine Pranobex in the Treatment of Cervical HPV Infections

The aim of the review article published in the journal Infection and Drug Resistance was to evaluate the available data on the potential use of inosine pranobex in the treatment of patients with a positive human papillomavirus finding in a cervical smear.

Source: Viral infections 13. 7. 2022

News How to Save a Leg from Amputation?

Feared complications in diabetics include defects in typical locations on the lower limbs. Their presence and frequent recurrences increase the risk of possible amputation of varying degrees, mainly depending on the involvement of deep structures, i.e., tendons, joint capsules, joints, and bones. How can this scenario be avoided? One answer might be HydroTherapy.

Source: Wound Healing 10. 8. 2022

News Idiopathic Pulmonary Fibrosis: Rare Disease with Severe Prognosis

Idiopathic pulmonary fibrosis (IPF) represents a diagnostic and therapeutic challenge. This rare diffuse primary fibroproliferative involvement of lung tissue is characterized by progressive exertional dyspnea, with antifibrotic treatment being the first-line therapeutic modality.

Source: Pulmonary Fibrosis 14. 4. 2020

Články časopisu Can affecting of subchondral bone slow the progression of osteoarthritis?

Author of the article: Pavelka Karel Source: Clinical Osteology | 2/2019 2. 9. 2019

News When to Consider Gaucher Disease and How to Diagnose It Early and Correctly

Considering Gaucher disease (GD) as a cause of a patient's problems, especially in the case of splenomegaly and bleeding manifestations, is very important, regardless of age. Screening using the dry blood spot method is available and very simple.

Source: Rare Diseases in Hematology 16. 5. 2023

News Polatuzumab Vedotin in the Treatment of NHL -⁠ News from the 25th EHA Congress

Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.

Source: Non-Hodgkin Lymphomas and CLL 29. 9. 2020

News Domestic application of biological asthma treatment improves quality of life and reduces doctor visits

The benefits of the possibility of home application of omalizumab, a monoclonal antibody indicated for patients with severe allergic asthma, are summarized by Dr. Jakub Novosad, Ph.D., from the Institute of Clinical Immunology and Allergology, Charles University Medical Faculty and University Hospital Hradec Králové.

Source: Asthma under control 9. 4. 2020